Methotrexate Treatment in Cases of Ectopic Pregnancy With Relative Contraindications

Condition(s) studied

Investigational drug(s) / intervention(s)

Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond: MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy

Study summary

Study Description (For Patients, Families, and Healthcare Providers)

Purpose:

The aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated.

Background:

Methotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population.

Method:

The study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data.

Why Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.

Eligibility

Primary outcome measure(s)

• Change in serum β-hCG levels (IU/L) — Days 0, 4, and 7 after methotrexate administration
  Serum beta-human chorionic gonadotropin levels measured via blood test on days 0, 4, and 7 of methotrexate treatment.

Trial sites (1)

More Bagcilar Training and Research Hospital trials in Turkey

Other trials for the same condition